Practical Insights on the Identification and Management of Patients with Chronic Migraine
Tóm tắt
Từ khóa
Tài liệu tham khảo
Headache Classification Committee of the International Headache Society. The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018;38:1–211.
Natoli JL, Manack A, Dean B, et al. Global prevalence of chronic migraine: a systematic review. Cephalalgia. 2010;30:599–609.
Buse DC, Manack AN, Fanning KM, et al. Chronic migraine prevalence, disability, and sociodemographic factors: results from the American Migraine Prevalence and Prevention study. Headache. 2012;52:1456–70.
May A, Schulte LH. Chronic migraine: risk factors, mechanisms and treatment. Nat Rev Neurol. 2016;12:455–64.
Serrano D, Lipton RB, Scher AI, et al. Fluctuations in episodic and chronic migraine status over the course of 1 year: implications for diagnosis, treatment and clinical trial design. J Headache Pain. 2017;18:101.
Medrea I, Christi S. Chronic migraine - evolution of the concept and clinical implications. Headache. 2018;58:1495–500.
Goadsby PJ, Evers S. International classification of headache disorders—ICHD-4 alpha. Cephalalgia. 2020;40:887–8.
Blumenfeld AM, Varon SF, Wilcox TK, et al. Disability, HRQoL and resource use among chronic and episodic migraineurs: results from the International Burden of Migraine Study (IBMS). Cephalalgia. 2011;31:301–15.
Bigal ME, Serrano D, Reed M, Lipton RB. Chronic migraine in the population: burden, diagnosis, and satisfaction with treatment. Neurology. 2008;71:559–66.
Manack Adams A, Serrano D, Buse DC, et al. The impact of chronic migraine: The Chronic Migraine Epidemiology and Outcomes (CaMEO) Study methods and baseline results. Cephalalgia. 2015;35:563–78.
Lipton RB, Manack Adams A, Buse DC, Fanning KM, Reed ML. A comparison of the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study and American Migraine Prevalence and Prevention (AMPP) Study: demographics and headache-related disability. Headache. 2016;56:1280–9.
Buse DC, Manack A, Serrano D, Turkel C, Lipton RB. Sociodemographic and comorbidity profiles of chronic migraine and episodic migraine sufferers. J Neurol Neurosurg Psychiatry. 2010;81:428–32.
Wang SJ, Wang PJ, Fuh JL, Peng KP, Ng K. Comparisons of disability, quality of life, and resource use between chronic and episodic migraineurs: a clinic-based study in Taiwan. Cephalalgia. 2013;33:171–81.
Stokes M, Becker WJ, Lipton RB, et al. Cost of health care among patients with chronic and episodic migraine in Canada and the USA: results from the International Burden of Migraine Study (IBMS). Headache. 2011;51:1058–77.
Bloudek LM, Stokes M, Buse DC, et al. Cost of healthcare for patients with migraine in five European countries: results from the International Burden of Migraine Study (IBMS). J Headache Pain. 2012;13:361–78.
Sanderson JC, Devine EB, Lipton RB, et al. Headache-related health resource utilisation in chronic and episodic migraine across six countries. J Neurol Neurosurg Psychiatry. 2013;84:1309–17.
Messali A, Sanderson JC, Blumenfeld AM, et al. Direct and indirect costs of chronic and episodic migraine in the United States: a web-based survey. Headache. 2016;56:306–22.
Negro A, Sciattella P, Rossi D, Guglielmetti M, Martelletti P, Mennini FS. Cost of chronic and episodic migraine patients in continuous treatment for two years in a tertiary level headache Centre. J Headache Pain. 2019;20:120.
Dodick DW, Loder EW, Manack Adams A, et al. Assessing barriers to chronic migraine consultation, diagnosis, and treatment: results from the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study. Headache. 2016;56:821–34.
Pavlovic JM, Yu JS, Silberstein SD, et al. Development of a claims-based algorithm to identify potentially undiagnosed chronic migraine patients. Cephalalgia. 2019;39:465–76.
Pavlovic J, Yu J, Silberstein S, et al. Economic burden, migraine treatment patterns, and opioid utilization among potentially undiagnosed chronic migraine, diagnosed chronic, and diagnosed episodic migraine patients in a large medical group [abstract G31]. J Manag Care Spec Pharm. 2018;24(10-a suppl):S55.
Pavlovic JM, Yu JS, Silberstein SD, et al. Evaluation of the 6-item Identify Chronic Migraine screener in a large medical group. Headache. 2021;61:335–42.
Sacco S, Benemei S, Cevoli S, et al. Development and validation of the ID-EC - the ITALIAN version of the identify chronic migraine. J Headache Pain. 2019;20:15.
Tepper SJ, Dahlöf CG, Dowson A, et al. Prevalence and diagnosis of migraine in patients consulting their physician with a complaint of headache: data from the Landmark Study. Headache. 2004;44:856–64.
Minen MT, Loder E, Tishler L, Silbersweig D. Migraine diagnosis and treatment: a knowledge and needs assessment among primary care providers. Cephalalgia. 2016;36:358–70.
Aljunaid MA, Jamal HH, Mubarak AA, Bardisi W. Levels and determinants of knowledge about chronic migraine diagnosis and management among primary health-care physicians in ministry of health, Jeddah 2019. J Family Med Prim Care. 2020;9:2324–31.
Martelletti P. The therapeutic armamentarium in migraine is quite elderly. Expert Opin Drug Metab Toxicol. 2015;11:175–7.
Steiner TJ, Jensen R, Katsarava Z, et al. Aids to management of headache disorders in primary care (2nd edition): on behalf of the European Headache Federation and Lifting The Burden: the Global Campaign against Headache. J Headache Pain. 2019;20:57.
Becker WJ. The diagnosis and management of chronic migraine in primary care. Headache. 2017;57:1471–81.
Katsarava Z, Buse DC, Manack AN, Lipton RB. Defining the differences between episodic migraine and chronic migraine. Curr Pain Headache Rep. 2012;16:86–92.
GBD 2016 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2016;390:1211–59.
Negro A, Martelletti P. Patient selection for migraine preventive treatment with anti-CGRP(r) monoclonal antibodies. Expert Rev Neurother. 2019;19:769–76.
Martelletti P, Guglielmetti M. Approaching the appropriate pharmacotherapy of menstrual migraine. Expert Rev Neurother. 2020;20:1–2.
Mehuys E, Paemeleire K, Van HT, et al. Self-medication of regular headache: a community pharmacy-based survey. Eur J Neurol. 2012;19:1093–9.
Muzina DJ, Chen W, Bowlin SJ. A large pharmacy claims-based descriptive analysis of patients with migraine and associated pharmacologic treatment patterns. Neuropsychiatr Dis Treat. 2011;7:663–72.
Brusa P, Allais G, Scarinzi C, et al. Self-medication for migraine: a nationwide cross-sectional study in Italy. PLoS ONE. 2019;14:e0211191.
Donnet A, Lantéri-Minet M, Aucoin F, Allaf B. Use and overuse of antimigraine drugs by pharmacy personnel in France: COTA survey. Headache. 2009;49:1014–21.
Takahashi TT, Ornello R, Quatrosi G, et al. Medication overuse and drug addiction: a narrative review from addiction perspective. J Headache Pain. 2021;22:32.
Hindiyeh NA, Zhang N, Farrar M, Banerjee P, Lombard L, Aurora SK. The role of diet and nutrition in migraine triggers and treatment: a systematic literature review. Headache. 2020;60:1300–16.
Sarker MA, Rahman M, Harun-Or-Rashid M, et al. Association of smoked and smokeless tobacco use with migraine: a hospital-based case-control study in Dhaka, Bangladesh. Tob Induc Dis. 2013;11:15.
Burch RC, Buse DC, Lipton RB. Migraine: epidemiology, burden, and comorbidity. Neurol Clin. 2019;37:631–49.
Blumenfeld AM. Clinician-patient dialogue about preventive chronic migraine treatment. J Prim Care Community Health. 2020;11:2150132720959935.
Goadsby PJ, Lantéri-Minet M, Michel MC, et al. 21st century headache: mapping new territory. J Headache Pain. 2021;22:19.